Association of significant financial burden with survival for head and neck cancer patients treated with radiation therapy.
Financial support
Head and neck neoplasms
Kaplan-Meier Analysis
Matched-pair analysis
Oral cancer
Survival
Journal
Oral oncology
ISSN: 1879-0593
Titre abrégé: Oral Oncol
Pays: England
ID NLM: 9709118
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
received:
07
08
2020
revised:
04
01
2021
accepted:
17
01
2021
pubmed:
13
2
2021
medline:
18
11
2021
entrez:
12
2
2021
Statut:
ppublish
Résumé
To assess the association between financial toxicity and survival in patients with head and neck cancer (HNC). Using a single-institution database, we retrospectively reviewed HNC patients treated at Roswell Park Comprehensive Cancer Center treated with definitive or postoperative radiation therapy between 2013 and 2017. Kaplan-Meier method and log-rank tests were used to analyze survival outcomes. Propensity score matching on all clinically relevant baseline characteristics was performed to address selection bias. All statistical tests were two-sided and those less than 0.05 were considered statistically significant. Of a total of 284 HNC patients (age: median 61 years, IQR 55-67; 220 [77.5%] men), 204 patients (71.8%) received definitive radiation and 80 patients (28.2%) received adjuvant radiation. There were 41 patients (14.4%) who reported high baseline financial toxicity. Chemotherapy was used in 237 patients (83.5%). On multivariable analysis, those with high financial toxicity exhibited worse overall survival (hazards ratio [HR] 1.75, 95% confidence interval [CI] 1.05-2.94, p = 0.03) and cancer specific survival (HR 2.28, 95% CI 1.31-3.96, p = 0.003). On matched pair analysis of 66 patients, high financial toxicity remained associated with worse OS (HR 2.72, 95% CI 1.04-7.09, p = 0.04) and CSS (HR 3.75, 95% CI 1.22-11.5, p = 0.02). HNC patient reported baseline financial toxicity was significantly correlated with both decreased overall and cancer specific survival. These significant correlations held after match pairing. Further research is warranted to investigate the impact of financial toxicity in HNC and mitigate its risk.
Identifiants
pubmed: 33578203
pii: S1368-8375(21)00019-1
doi: 10.1016/j.oraloncology.2021.105196
pmc: PMC10353569
mid: NIHMS1898874
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
105196Subventions
Organisme : NCI NIH HHS
ID : P30 CA016056
Pays : United States
Informations de copyright
Copyright © 2021 Elsevier Ltd. All rights reserved.
Références
Pharm Stat. 2011 Mar-Apr;10(2):150-61
pubmed: 20925139
Ann Oncol. 2019 Jul 1;30(7):1061-1070
pubmed: 31046080
Oral Oncol. 2019 Aug;95:187-193
pubmed: 31345389
Am J Clin Oncol. 2009 Dec;32(6):587-91
pubmed: 19581794
World J Clin Oncol. 2012 Apr 10;3(4):57-62
pubmed: 22553505
Cancer. 2019 Apr 15;125(8):1281-1289
pubmed: 30645761
Medicine (Baltimore). 2015 Jul;94(27):e1097
pubmed: 26166098
Cancer. 2013 Mar 15;119(6):1257-65
pubmed: 23225522
J Clin Epidemiol. 2008 Apr;61(4):344-9
pubmed: 18313558
Ann Oncol. 2020 Jan;31(1):96-102
pubmed: 31912803
J Oncol Pract. 2014 May;10(3):162-7
pubmed: 24839274
Future Oncol. 2019 May;15(15):1697-1705
pubmed: 30977688
Am J Manag Care. 2015 Sep;21(9):607-15
pubmed: 26618364
Health Aff (Millwood). 2013 Jun;32(6):1143-52
pubmed: 23676531
J Clin Oncol. 2016 Mar 20;34(9):980-6
pubmed: 26811521
J Clin Oncol. 2015 Aug 10;33(23):2563-77
pubmed: 26101248
Oral Oncol. 2020 Jun 16;109:104854
pubmed: 32559724
Strahlenther Onkol. 2016 Aug;192(8):552-60
pubmed: 27323753
Br J Oral Maxillofac Surg. 2012 Jul;50(5):410-6
pubmed: 22000023
J Oncol Pract. 2017 Apr;13(4):e310-e318
pubmed: 28195811
JAMA Otolaryngol Head Neck Surg. 2019 Mar 01;145(3):239-249
pubmed: 30789634
J Oncol Pract. 2016 Jul;12(7):e755-64
pubmed: 27328795
Oncologist. 2015 Oct;20(10):1199-204
pubmed: 26330457
J Clin Oncol. 2011 Jul 10;29(20):2821-6
pubmed: 21632508
J Clin Oncol. 2019 Aug 1;37(22):1909-1918
pubmed: 31163012
J Clin Oncol. 2016 May 20;34(15):1732-40
pubmed: 26926678
Oral Oncol. 2020 Feb;101:104521
pubmed: 31877502
BMC Cancer. 2011 Aug 15;11:353
pubmed: 21843358
Cancer. 2004 May 15;100(10):2048-51
pubmed: 15139045
J Oncol Pract. 2014 Sep;10(5):332-8
pubmed: 24865220
Support Care Cancer. 2020 Mar;28(3):1131-1139
pubmed: 31201545
Head Neck. 2013 May;35(5):684-8
pubmed: 22619040
CA Cancer J Clin. 2018 Mar;68(2):153-165
pubmed: 29338071
Support Care Cancer. 2006 Feb;14(2):193-9
pubmed: 16059680
Cancer. 2004 Jan 15;100(2):425-32
pubmed: 14716781
J Oncol Pract. 2014 Sep;10(5):e368-72
pubmed: 24865219
Surgery. 2020 Jul;168(1):167-172
pubmed: 32197785
Cancer. 2018 Sep 15;124(18):3668-3676
pubmed: 30033631
JAMA Otolaryngol Head Neck Surg. 2018 Oct 1;144(10):913-922
pubmed: 30326060